CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

PK1; EGVEGF; PRK1, PROK1; Prokineticin 1; Black Mamba Toxin-Related Protein; Mambakine

  • CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) Packages (Simulation)
  • CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) Packages (Simulation)
  • CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) Results demonstration
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Specificity of the CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

This assay has high sensitivity and excellent specificity for detection of Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF).
No significant cross-reactivity or interference between Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) and analogues was observed.

Recovery of the CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

Matrices listed below were spiked with certain level of recombinant Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) and the recovery rates were calculated by comparing the measured value to the expected amount of Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 92-102 95
EDTA plasma(n=5) 94-102 97
heparin plasma(n=5) 92-99 95

Precision of the CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity of the CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 94-101% 96-105% 95-105% 85-99%
EDTA plasma(n=5) 99-105% 97-104% 80-105% 88-99%
heparin plasma(n=5) 87-94% 79-97% 78-102% 83-93%

Stability of the CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Assay procedure summary of the CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 3 times;
5. Add 100µL prepared Detection Reagent B. Incubate 30 minutes at 37°C;
6. Aspirate and wash 5 times;
7. Add 100µL Substrate Solution. Incubate 10 minutes at 37°C;
8. Read RLU value immediately.

Test principle of the CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF)

The microplate provided in this kit has been pre-coated with an antibody specific to Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF). Standards or samples are then added to the appropriate microplate wells with a biotin-conjugated antibody specific to Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF). Next, Avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. Then the mixture of substrate A and B is added to generate glow light emission kinetics. Upon plate development, the intensity of the emitted light is proportional to the Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) level in the sample or standard.;

Related products

Catalog No. Organism species: Homo sapiens (Human) Applications (RESEARCH USE ONLY!)
RPA024Hu01 Recombinant Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) Positive Control; Immunogen; SDS-PAGE; WB.
APA024Hu01 Active Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) Cell culture; Activity Assays.
PAA024Hu01 Polyclonal Antibody to Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) WB; IHC; ICC; IP.
MAA024Hu22 Monoclonal Antibody to Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) WB; IHC; ICC; IP.
SEA024Hu ELISA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) Enzyme-linked immunosorbent assay for Antigen Detection.
SCA024Hu CLIA Kit for Endocrine Gland Derived Vascular Endothelial Growth Factor (EG-VEGF) Chemiluminescent immunoassay for Antigen Detection.
GUESTBOOK